E-submission
Search
- Page Path
- HOME > Search
Reviews
- Pathologic interpretation of endoscopic ultrasound–guided fine needle aspiration cytology/biopsy for pancreatic lesions
- Haeryoung Kim, Kee-Taek Jang
- J Pathol Transl Med. 2020;54(5):367-377. Published online August 31, 2020
- DOI: https://doi.org/10.4132/jptm.2020.07.21
- 4,972 View
- 185 Download
- 3 Web of Science
- 3 Crossref
-
Abstract
PDF - Pathologic interpretation of endoscopic ultrasound–guided fine needle aspiration (EUS-FNA) cytology/biopsy specimens is one of the most challenging tasks in cytology and surgical pathology practice, as the procedure often yields minimal amounts of diagnostic material and contains contaminants, such as blood cells and normal intestinal mucosa. EUS-FNA cytology/biopsy will nevertheless become a more popular procedure for evaluation of various pancreatic lesions because they are difficult to approach with conventional endoscopic procedures. Pathologists should understand the structural differences and limitations of EUS-FNA that make pathologic diagnosis difficult. Ancillary tests are available for differential diagnosis of EUS-FNA for various pancreatic lesions. Immunostains are the most commonly used ancillary tests, and pathologists should able to choose the necessary panel for differential diagnosis. Pathologists should review clinical history and radiologic and/or EUS findings before selecting an immunostain panel and making a pathologic diagnosis. In addition, one’s threshold of malignancy should be adjusted according to the appropriate clinical setting to avoid under-evaluation of pathologic diagnoses. Clinico-pathologic correlation is essential in pathologic evaluation of EUS-FNA for pancreatic lesions. Pathologists can reduce errors by correlating clinical and radiologic findings when evaluating EUS-FNA. Some molecular tests can be applied in differential diagnosis of pancreatic neoplastic and cystic lesions. Molecular data should be used as supportive evidence of a specific disease entity, rather than direct evidence, and should be correlated with clinico-pathologic findings to avoid errors in pathologic diagnosis.
-
Citations
Citations to this article as recorded by
- A prospective randomized noninferiority trial comparing conventional smears and SurePathTM liquid-based cytology in endoscopic ultrasound-guided sampling of esophageal, gastric, and duodenal lesions
Jae Chang Jun, Sang Hyub Lee, Han Myung Lee, Sang Gyun Kim, Hyunsoo Chung, Joo Seong Kim, Namyoung Park, Jin Ho Choi, Yoonjin Kwak, Soo-Jeong Cho
Medicine.2023; 102(29): e34321. CrossRef - Double Ki-67 and synaptophysin labeling in pancreatic neuroendocrine tumor biopsies
Bokyung Ahn, Jin Kying Jung, HaeSung Jung, Yeon-Mi Ryu, Yeon Wook Kim, Tae Jun Song, Do Hyun Park, Dae wook Hwang, HyungJun Cho, Sang-Yeob Kim, Seung-Mo Hong
Pancreatology.2022; 22(3): 427. CrossRef - Comparison of Endoscopic Ultrasound-Guided Fine Needle Aspiration with 19-Gauge and 22-Gauge Needles for Solid Pancreatic Lesions
Changjuan Li, Jianwei Mi, Fulai Gao, Xinying Zhu, Miao Su, Xiaoli Xie, Dongqiang Zhao
International Journal of General Medicine.2021; Volume 14: 10439. CrossRef
- A prospective randomized noninferiority trial comparing conventional smears and SurePathTM liquid-based cytology in endoscopic ultrasound-guided sampling of esophageal, gastric, and duodenal lesions
- Genomic Landscapes of Pancreatic Neoplasia
- Laura D. Wood, Ralph H. Hruban
- J Pathol Transl Med. 2015;49(1):13-22. Published online January 15, 2015
- DOI: https://doi.org/10.4132/jptm.2014.12.26
- 11,430 View
- 112 Download
- 17 Web of Science
- 13 Crossref
-
Abstract
PDF
- Pancreatic cancer is a deadly disease with a dismal prognosis. However, recent advances in sequencing and bioinformatic technology have led to the systematic characterization of the genomes of all major tumor types in the pancreas. This characterization has revealed the unique genomic landscape of each tumor type. This knowledge will pave the way for improved diagnostic and therapeutic approaches to pancreatic tumors that take advantage of the genetic alterations in these neoplasms.
-
Citations
Citations to this article as recorded by- Pancreatoblastoma with a novel fusion gene ofIQSEC1‐RAF1
Hironori Goto, Yuhki Koga, Kenichi Kohashi, Hiroaki Ono, Junkichi Takemoto, Toshiharu Matsuura, Tatsuro Tajiri, Kenji Ihara, Yoshinao Oda, Shouichi Ohga
Pediatric Blood & Cancer.2023;[Epub] CrossRef - Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography–based radiomics and genetic alterations of pancreatic ductal adenocarcinoma
Chae Hong Lim, Young Seok Cho, Joon Young Choi, Kyung-Han Lee, Jong Kyun Lee, Ji Hye Min, Seung Hyup Hyun
European Journal of Nuclear Medicine and Molecular Imaging.2020; 47(9): 2113. CrossRef - NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS
Mitali Chattopadhyay, Ravinder Kodela, Gabriela Santiago, Thuy Tien C. Le, Niharika Nath, Khosrow Kashfi
Biochemical Pharmacology.2020; 176: 113857. CrossRef - Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Friederike Inga Nollmann, Dietrich Alexander Ruess
Biomedicines.2020; 8(8): 281. CrossRef - Ancillary Techniques in Cytologic Specimens Obtained from Solid Lesions of the Pancreas: A Review
Jonas J. Heymann, Momin T. Siddiqui
Acta Cytologica.2020; 64(1-2): 103. CrossRef - DNA polymerase η mutational signatures are found in a variety of different types of cancer
Igor B. Rogozin, Alexander Goncearenco, Artem G. Lada, Subhajyoti De, Vyacheslav Yurchenko, German Nudelman, Anna R. Panchenko, David N. Cooper, Youri I. Pavlov
Cell Cycle.2018; 17(3): 348. CrossRef - Genetics of Pancreatic Neoplasms and Role of Screening
Venkata S. Katabathina, Omid Y. Rikhtehgar, Anil K. Dasyam, Rohan Manickam, Srinivasa R. Prasad
Magnetic Resonance Imaging Clinics of North America.2018; 26(3): 375. CrossRef - Team work and cytopathology molecular diagnosis of solid pancreatic lesions
Carlo Fabbri, Giulia Gibiino, Adele Fornelli, Vincenzo Cennamo, Daniela Grifoni, Michela Visani, Giorgia Acquaviva, Matteo Fassan, Sirio Fiorino, Silvia Giovanelli, Marco Bassi, Stefania Ghersi, Giovanni Tallini, Elio Jovine, Antonio Gasbarrini, Dario de
Digestive Endoscopy.2017; 29(6): 657. CrossRef - Mutational signatures and mutable motifs in cancer genomes
Igor B. Rogozin, Youri I. Pavlov, Alexander Goncearenco, Subhajyoti De, Artem G. Lada, Eugenia Poliakov, Anna R. Panchenko, David N. Cooper
Briefings in Bioinformatics.2017;[Epub] CrossRef - The evolving field of genomic biomarkers to characterize pancreatic cystic neoplasia by EUS-guided FNA
Ferga C. Gleeson, Michael J. Levy
Gastrointestinal Endoscopy.2016; 83(1): 149. CrossRef - MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors
Rui Gradiz, Henriqueta C. Silva, Lina Carvalho, Maria Filomena Botelho, Anabela Mota-Pinto
Scientific Reports.2016;[Epub] CrossRef - p53 and p16/p19 Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells
Stephanie Azzopardi, Sharon Pang, David S. Klimstra, Yi-Chieh Nancy Du
Neoplasia.2016; 18(10): 610. CrossRef - MicroRNA-506 participates in pancreatic cancer pathogenesis by targeting PIM3
JUNDONG DU, XI ZHENG, SHOUWANG CAI, ZIMAN ZHU, JINGWANG TAN, BIN HU, ZHIQIANG HUANG, HUABO JIAO
Molecular Medicine Reports.2015; 12(4): 5121. CrossRef
- Pancreatoblastoma with a novel fusion gene ofIQSEC1‐RAF1
Case Report
- Triple Synchronous Cancers of Stomach, Pancreas, and Kidney.
- Seung Koo Lee, Byung Ha Choi, Shin Kwang Khang, Byung Sik Kim, Jooryung Huh
- Korean J Pathol. 2001;35(6):547-550.
- 1,484 View
- 10 Download
-
Abstract
- Synchronous occurrence of triple distinct malignant tumors in the same patient is very rare. We report a unique case of a triple cancer occurring in a 70-year-old Korean woman with synchronous signet ring cell carcinoma of the stomach, renal cell carcinoma of the conventional type of the left kidney, and invasive ductal adenocarcinoma and intraductal papillary carcinoma of the pancreas. All three cancers were successfully resected simultaneously by total gastrectomy, nephrectomy, and partial pancreatectomy with corresponding lymphadenectomies. This patient tolerated these surgical procedures well and led a normal healthy life during the 18 months of follow-up. In summary, a successful resection of synchronous triple cancers which has never been previously reported in such combination, is described.
First
Prev
